Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) has set December 20, 2024, as the date for its 2024 Annual Meeting of Stockholders. Shareholders as of October 25, 2024, will be eligible to vote at the meeting, with new deadlines for proposal submissions in place.
In compliance with SEC rules, proposals must be received by the Company's Secretary by October 7, 2024, for inclusion in the proxy materials. Stockholders intending to solicit proxies for director nominees must adhere to the universal proxy rules by October 21, 2024.
Recent developments include the registration of additional shares of common stock and new stock offerings by Salarius Pharmaceuticals, Inc. The company also decided to discontinue a clinical trial and faced a partial clinical hold by the FDA.
InvestingPro Insights
InvestingPro data shows SLRX's market capitalization at $2.09 million, with the stock trading near its 52-week low. The company holds more cash than debt but is not profitable, with high price volatility in recent trading.
Investors should consider these insights when evaluating SLRX and its upcoming annual meeting, as they may impact shareholder decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Analysis: Salarius Pharmaceuticals, Inc. has announced its 2024 Annual Meeting of Stockholders, setting important dates for shareholders to participate and submit proposals. The company's recent actions, including stock offerings and clinical trial developments, have influenced its financial standing and market performance. Investors should be aware of these factors when considering their investment decisions in SLRX.
